BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3
BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3
Body unavailable. Use the original source.
BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.